Analyzing...
Loading company...
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 1,412 full-time employees. The company went IPO on 2002-04-03. The firm operates through the manufacture of pharmaceutical formulation segment. The firm is primarily engaged in the research, manufacturing and marketing of generic pharmaceutical formulations with three state-of-the-art facilities in India, the United Kingdom and the United States. The company marks its presence across different therapeutic areas in the region, such as pain management, diabetes, cough and cold, neurology, cardiovascular and hormonal treatment. The firm has a manufacturing facility for the manufacture of oral solid tablets, soft gelatin capsules and hard capsules in Goa. The company also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The firm has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,951 Cr revenue.
COGS 43.3%, employees 14.3%.
“Our next milestone is 4,000 crores...anywhere between two to three years is what we should write our first milestone”
“revenue grew by 10.”
“4,000 crores by next two to three years (FY28/29), then 5,000 crores milestone”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 13.8%▲ | 10.3% |
| ROCE | 17.5%▲ | 13.7% |
| Net Margin | 13.8%▲ | 7.6% |
| EBITDA Margin | 22.5%▲ | 15.4% |
| Debt To Equity | 0.01x▼ | 0.15x |
| Rev Growth 3yr | 16.6%▲ | 10.0% |
| EPS Growth 3yr | 16.4%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,951 Cr | ₹262 Cr -88.0% | ₹2,177 Cr +17.6% | ₹1,852 Cr +24.2% | ₹1,491 Cr +8.3% | ₹1,376 Cr +21.3% | ₹1,134 Cr +13.4% | ₹1,000 Cr |
| Other Income | ₹83 Cr | ₹7 Cr -86.0% | ₹50 Cr -15.0% | ₹59 Cr +41.7% | ₹42 Cr +525.2% | ₹7 Cr | ₹0.33 Cr -92.9% | ₹5 Cr |
| Total Income | ₹3,033 Cr | ₹269 Cr -87.9% | ₹2,228 Cr +16.6% | ₹1,911 Cr +24.7% | ₹1,533 Cr +10.8% | ₹1,383 Cr +21.9% | ₹1,135 Cr +12.9% | ₹1,005 Cr |
| COGS | ₹1,277 Cr | ₹114 Cr -89.0% | ₹1,038 Cr +12.7% | ₹921 Cr +28.5% | ₹717 Cr +20.5% | ₹595 Cr +9.2% | ₹545 Cr +9.4% | ₹498 Cr |
| ₹2,473 Cr | ₹219 Cr -87.9% | ₹1,804 Cr +14.6% | ₹1,574 Cr +22.5% | ₹1,285 Cr +18.9% | ₹1,081 Cr +10.6% | ₹977 Cr +8.5% | ₹900 Cr | |
| Profit Before Tax | ₹561 Cr | ₹50 Cr -88.1% | ₹424 Cr +25.4% | ₹338 Cr +36.4% | ₹248 Cr -18.1% | ₹302 Cr +92.2% | ₹157 Cr +50.7% | ₹104 Cr |
| ₹140 Cr | ₹12 Cr -88.8% | ₹109 Cr +50.2% | ₹72 Cr +19.2% | ₹61 Cr -4.6% | ₹64 Cr +74.7% | ₹36 Cr +52.6% | ₹24 Cr | |
| Net Profit | ₹420 Cr +997.9% | ₹38 Cr -87.8% | ₹315 Cr +18.7% | ₹265 Cr +42.0% | ₹187 Cr -21.7% | ₹239 Cr +97.5% | ₹121 Cr +50.1% | ₹80 Cr |
| Profit (Owners) | ₹418 Cr +992.2% | ₹38 Cr -87.8% | ₹314 Cr +18.3% | ₹265 Cr +42.0% | ₹187 Cr -21.7% | ₹239 Cr +97.5% | ₹121 Cr +58.8% | ₹76 Cr |
| Minority Interest | ₹2 Cr | ₹0.00 Cr -100.0% | ₹0.94 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹4 Cr |
| Other Comprehensive Income | ₹176 Cr | ₹5 Cr -83.2% | ₹29 Cr -45.2% | ₹52 Cr +3.8% | ₹50 Cr | ₹0.47 Cr -92.9% | ₹7 Cr ↑ Recovery | (₹0.40 Cr) |
| EPS | ₹9.23 | ₹0.84 | ₹6.93 | ₹5.85 | ₹4.56 | ₹5.83 | ₹2.95 | ₹1.86 |
| Diluted Shares | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for AGM Intimation
Marksans Pharma Limited has informed the Exchange about acquisition of 100 percent share capital of ABCnow GmbH.
Marksans Pharma Limited has informed the Exchange about Second 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK" Phase IV
Marksans Pharma Limited has informed the Exchange about Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026
Marksans Pharma Limited has informed the Exchange regarding a press release dated July 08, 2026, titled "Marksans Pharma signed a definitive agreement to acquire 100 percent share capital of a German ...
Marksans Pharma Limited has informed the Exchange about Update on acquisition of QliniQ B.V.
Marksans Pharma Limited has informed the Exchange that India Ratings and Research has revised the outlook for the Company s bank loan facilities to Positive from Stable
Marksans Pharma Limited has informed the Exchange about Schedule for Virtual Investor Conference
Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet on Q4 FY 26 Audited Financial Results
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Second 100 day Campaign- "Saksham Niveshak"
Marksans Pharma Limited has informed the Exchange about Second 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"'.
Marksans Pharma Limited has informed the Exchange regarding a press release dated Jun 01, 2026, titled "Marksans Pharma to Acquire 100% of Netherlands-based QliniQ B.V., Strengthening Presence in Euro...
Marksans Pharma Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Marksans Pharma Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT ₹3,000...
Marksans Pharma Limited has informed the Exchange about Investor Presentation
Marksans Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 0.90 per equity share.